[en] Pan-genotypic cost-effectiveness has been demonstrated for sofosbuvir in comparison for the current standard of care in HCV in Belgium. Overall, the wheghted pan-genotypic ICER is 15.575 Euros.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
De Groote, K
Michielsen, P
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Language :
English
Title :
Cost-effectiveness model for sofosbuvir in chronic hepatitis C
Publication date :
November 2014
Event name :
17th Annual European Congress International Society for Pharmacoeconomic and outcomes research
